Can Softer Admissions at Select Medical (SEM) Reveal Shifts in Its Competitive Edge?

• In recent days, Select Medical Holdings reported a decline in patient admissions alongside an outlook for softer sales across its network of healthcare facilities in the United States.
• This development points to emerging operational challenges that could weigh on revenue streams and test the company's ability to adapt in the competitive healthcare sector.
• We will explore how concerns around weakening patient volumes may shift the investment narrative for Select Medical Holdings going forward.

The end of cancer? These 28 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.

Select Medical Holdings Investment Narrative Recap

Shareholders in Select Medical Holdings are generally buying into the idea that demographic shifts and the need for post-acute care can drive steady patient volumes and revenue growth. Recent reports of declining admissions and a softer sales outlook could dampen optimism around near-term earnings momentum, while bringing sharper focus to the company’s exposure to regulatory and reimbursement risks, particularly in its critical illness recovery segment.

Of the recent announcements, the upcoming Q3 2025 earnings release scheduled for October 30 stands out as especially relevant, as it should offer essential updates on how the company’s operations are responding to current pressures and whether management adjusts its guidance given recent volume trends and financial headwinds.

Yet, despite positive long-term factors, the risk of further reimbursement changes in government programs remains something every investor should keep front of mind...

Read the full narrative on Select Medical Holdings (it's free!)

Select Medical Holdings is projected to reach $6.1 billion in revenue and $233.8 million in earnings by 2028. This outlook assumes annual revenue growth of 5.1% and an increase in earnings of $152.7 million from the current $81.1 million.

Uncover how Select Medical Holdings' forecasts yield a $17.83 fair value, a 25% upside to its current price.

Exploring Other Perspectives

Simply Wall St Community members have shared two fair value estimates for Select Medical Holdings ranging from US$9.35 to US$17.83 per share. While opinions diverge, concern over ongoing Medicare reimbursement pressure presents a key variable likely to shape future results, so it is worth considering multiple points of view before making any assessment.

Explore 2 other fair value estimates on Select Medical Holdings - why the stock might be worth 35% less than the current price!

Build Your Own Select Medical Holdings Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Select Medical Holdings research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Select Medical Holdings research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Select Medical Holdings' overall financial health at a glance.

Want Some Alternatives?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• This technology could replace computers: discover 27 stocks that are working to make quantum computing a reality.
• The latest GPUs need a type of rare earth metal called Neodymium and there are only 36 companies in the world exploring or producing it. Find the list for free.
• We've found 17 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com